These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 2787976)
1. Severe myocarditis following high-dose interleukin-2 administration. Samlowski WE; Ward JH; Craven CM; Freedman RA Arch Pathol Lab Med; 1989 Aug; 113(8):838-41. PubMed ID: 2787976 [TBL] [Abstract][Full Text] [Related]
2. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor. McDermott DF; Trehu EG; Mier JW; Sorce D; Rand W; Ronayne L; Kappler K; Clancy M; Klempner M; Atkins MB Clin Cancer Res; 1998 May; 4(5):1203-13. PubMed ID: 9607578 [TBL] [Abstract][Full Text] [Related]
3. Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer. Kragel AH; Travis WD; Steis RG; Rosenberg SA; Roberts WC Cancer; 1990 Oct; 66(7):1513-6. PubMed ID: 2208002 [TBL] [Abstract][Full Text] [Related]
4. Case report and brief review: IL-2-induced myocarditis. Eisner RM; Husain A; Clark JI Cancer Invest; 2004; 22(3):401-4. PubMed ID: 15493361 [TBL] [Abstract][Full Text] [Related]
5. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma. Margolin K; Atkins M; Sparano J; Sosman J; Weiss G; Lotze M; Doroshow J; Mier J; O'Boyle K; Fisher R; Campbell E; Rubin J; Federighi D; Bursten S Clin Cancer Res; 1997 Apr; 3(4):565-72. PubMed ID: 9815721 [TBL] [Abstract][Full Text] [Related]
6. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer. Acquavella N; Kluger H; Rhee J; Farber L; Tara H; Ariyan S; Narayan D; Kelly W; Sznol M J Immunother; 2008; 31(6):569-76. PubMed ID: 18528297 [TBL] [Abstract][Full Text] [Related]
7. [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study]. Schrader AJ; Heidenreich A; Hegele A; Olbert P; Varga Z; Hofmann R Aktuelle Urol; 2006 Nov; 37(6):429-35; quiz 423-4. PubMed ID: 17099831 [TBL] [Abstract][Full Text] [Related]
8. Increased disease activity in a patient with sarcoidosis after high dose interleukin 2 treatment for metastatic renal cancer. Logan TF; Bensadoun ES Thorax; 2005 Jul; 60(7):610-1. PubMed ID: 15994271 [TBL] [Abstract][Full Text] [Related]
9. Strategies to reduce side effects of interleukin-2: evaluation of the antihypotensive agent NG-monomethyl-L-arginine. Kilbourn RG; Fonseca GA; Trissel LA; Griffith OW Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S21-30. PubMed ID: 10685654 [TBL] [Abstract][Full Text] [Related]
10. Progressive anemia following combination therapy with interferon-alpha and interleukin-2 in a patient with metastatic renal cell carcinoma. Hosokawa Y; Kishino T; Ono T; Oyama N; Hayashi K; Momose H Int J Urol; 2004 Oct; 11(10):906-8. PubMed ID: 15479299 [TBL] [Abstract][Full Text] [Related]
11. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group. Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J; J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421 [TBL] [Abstract][Full Text] [Related]
12. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Kammula US; White DE; Rosenberg SA Cancer; 1998 Aug; 83(4):797-805. PubMed ID: 9708948 [TBL] [Abstract][Full Text] [Related]
13. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950 [TBL] [Abstract][Full Text] [Related]
14. High-dose interleukin-2 immunotherapy is safe for patients with metastatic renal cell carcinoma on dialysis. Brusky JP; Gailani F; Pathak A; Patel H; Aboseif S BJU Int; 2006 Feb; 97(2):279-80. PubMed ID: 16430629 [TBL] [Abstract][Full Text] [Related]
15. High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience. Shulman KL; Stadler WM; Vogelzang NJ Urology; 1996 Feb; 47(2):194-7. PubMed ID: 8607232 [TBL] [Abstract][Full Text] [Related]
16. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma. Amato RJ; Malya R; Rawat A Am J Clin Oncol; 2008 Jun; 31(3):237-43. PubMed ID: 18525301 [TBL] [Abstract][Full Text] [Related]
17. Phase I trial of simultaneous administration of interleukin 2 and interleukin 4 subcutaneously. Whitehead RP; Friedman KD; Clark DA; Pagani K; Rapp L Clin Cancer Res; 1995 Oct; 1(10):1145-52. PubMed ID: 9815906 [TBL] [Abstract][Full Text] [Related]
18. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. van der Vliet HJ; Koon HB; Yue SC; Uzunparmak B; Seery V; Gavin MA; Rudensky AY; Atkins MB; Balk SP; Exley MA Clin Cancer Res; 2007 Apr; 13(7):2100-8. PubMed ID: 17404092 [TBL] [Abstract][Full Text] [Related]
19. Myositis following treatment with high dose interleukin-2 for malignancy. Finger DR; Plotz PH; Heywood G J Rheumatol; 1995 Nov; 22(11):2188. PubMed ID: 8596171 [No Abstract] [Full Text] [Related]
20. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie. Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S; Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]